JUNEL FE 1.5/30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNEL FE 1.5/30 (JUNEL FE 1.5/30).
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: primarily reduced and conjugated, with CYP3A4 involvement. |
| Excretion | Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation. |
| Half-life | Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy. |
| Protein binding | Norethindrone: 60-80% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin (specific binding to SHBG not significant). |
| Volume of Distribution | Norethindrone: 2-4 L/kg; ethinyl estradiol: 5-10 L/kg. Clinical meaning: Indicates extensive tissue distribution and slow clearance; Vd may increase in obesity. |
| Bioavailability | Oral: Norethindrone ~60-70% (first-pass metabolism); ethinyl estradiol ~40-50% (presystemic conjugation in gut and liver). |
| Onset of Action | Oral: Onset of contraceptive effect within 7 days of consistent dosing; inhibition of ovulation occurs by day 7 of first cycle if taken on day 1 of menses. |
| Duration of Action | Oral: 24 hours (daily dosing required). Clinical notes: Continuous suppression of gonadotropins requires consistent daily intake; missed doses >24 hours increase failure risk. |
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment provided in labeling; use with caution in patients with renal impairment. GFR-based modifications not established. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) or active liver disease. No specific dose adjustment for mild impairment; use with caution. |
| Pediatric use | Not indicated for use before menarche. In post-menarche adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days placebo. |
| Geriatric use | Not indicated for use in postmenopausal women; no specific geriatric dosing considerations. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUNEL FE 1.5/30 (JUNEL FE 1.5/30).
| Breastfeeding | Excreted in breast milk in small amounts; M/P ratio for ethinyl estradiol approximately 0.04–0.30. Progestin M/P ratio variable. May reduce milk production and quality. Use only if necessary and with caution, especially in early postpartum period. |
| Teratogenic Risk | First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic effects, including potential genitourinary tract abnormalities. Postnatal effects: Possible long-term neurodevelopmental impacts reported in animal studies. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women >35 years who smoke should not use this product.
| Serious Effects |
["Hypersensitivity to any component","Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Benign or malignant liver tumor (current or history)","Hepatic adenoma or carcinomas","Active liver disease with abnormal function tests","Major surgery with prolonged immobilization","Diabetes with vascular involvement","Uncontrolled hypertension","Migraine with focal neurological symptoms (current or history)","Smoking in women >35 years"]
| Precautions | ["Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI)","Hepatic neoplasia risk","Liver disease (e.g., jaundice, hepatitis)","Elevated blood pressure","Gallbladder disease","Carbohydrate/lipid metabolic effects","Ocular lesions (e.g., retinal thrombosis)","Menstrual irregularities/breakthrough bleeding","Use in pregnancy (should be ruled out before initiation)","Depression"] |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure, liver function, glucose tolerance; fetal ultrasound for growth and anatomy if exposed during second/third trimester. Assess for signs of thromboembolism. |
| Fertility Effects | Returns to baseline after discontinuation with no permanent effect on fertility. Temporary delay in return to ovulation possible. |